What long‑term antiplatelet or anticoagulant therapy should a 48‑year‑old woman with migraines, prior transient ischemic attacks, Watchman left atrial appendage closure, patent foramen ovale closure, pulmonary vein isolation for atrial fibrillation, and a recent intracranial hemorrhage while on rivaroxaban (Xarelto) require?

Antiplatelet Therapy Only—No Anticoagulation After Intracranial Hemorrhage

Given this patient's intracranial hemorrhage on rivaroxaban, she should receive single antiplatelet therapy (SAPT) with aspirin 81 mg daily long-term, and all oral anticoagulation should be permanently discontinued. Her successful Watchman device (with confirmed good position and no residual shunt) and PFO closure have mechanically eliminated the primary stroke sources that would otherwise require anticoagulation for her atrial fibrillation.

Clinical Reasoning

Why No Anticoagulation

This patient has experienced the most feared complication of anticoagulation—intracranial bleeding. The 2020 ACC Expert Consensus explicitly addresses cerebrovascular disease with high recurrent hemorrhage risk, noting that "in patients with a concomitant diagnosis of cerebral amyloid angiopathy, the risk of recurrent intracranial hemorrhage is very high and generally precludes use of anticoagulation" 1. While her specific ICH etiology isn't stated, any intracranial hemorrhage on anticoagulation creates prohibitively high rebleeding risk with continued anticoagulation.

Why Watchman Changes Everything

The critical factor here is her successful Watchman device with TEE-confirmed good position and no residual shunt 1. The left atrial appendage is the source of >90% of AF-related thrombi. With mechanical LAA exclusion confirmed by imaging, her stroke risk from AF is dramatically reduced. Similarly, her PFO closure eliminates paradoxical embolism risk that contributed to her prior TIAs 2.

Why Antiplatelet Therapy Is Sufficient

After successful LAA closure with confirmed device endothelialization (which occurs by 45 days post-procedure), SAPT alone is the standard long-term regimen 3, 4, 5. The 2020 ACC guidelines support stopping all anticoagulation after the initial post-LAAC period when device position is confirmed 1. Her PVI for AFib further reduces AF burden, though this doesn't eliminate stroke risk without the Watchman.

Specific Long-Term Regimen

Aspirin 81 mg daily indefinitely is the recommended long-term therapy. Here's why:

• No DOAC: Rivaroxaban caused her ICH. All DOACs (apixaban, dabigatran, edoxaban) carry similar ICH risk and are contraindicated 1
• No warfarin: VKAs have even higher ICH rates than DOACs and offer no advantage here 2
• No dual antiplatelet therapy (DAPT): The standard post-Watchman protocol uses DAPT only for 1-6 months, then transitions to SAPT 3, 4. Since her devices were placed in the past (dates redacted but implied remote), she's beyond the DAPT window
• Aspirin over clopidogrel: While either SAPT agent is acceptable, aspirin is preferred for long-term secondary stroke prevention in patients with prior TIA when anticoagulation is contraindicated 1

Critical Monitoring Points

1. Confirm device integrity: Ensure repeat TEE at 6-12 months post-ICH shows maintained Watchman position, complete LAA seal, and no device-related thrombus (DRT). DRT occurs in 3-4% of cases and would complicate management 4, 5

2. Assess for residual shunts: Verify PFO closure remains complete. Any residual shunt might increase paradoxical embolism risk, though anticoagulation still wouldn't be appropriate given ICH history

3. Neuroimaging follow-up: Obtain brain MRI 3-6 months post-ICH to assess for cerebral amyloid angiopathy, microbleeds, or other bleeding-prone pathology that would further contraindicate any future anticoagulation consideration

4. Migraine management: Her migraines may have been related to PFO (migraine-PFO association is well-established). Monitor whether PFO closure improved migraine frequency—this would support successful closure 6

Common Pitfalls to Avoid

Do not restart anticoagulation "once the bleed resolves." Unlike subdural hematomas from trauma where anticoagulation might eventually resume, spontaneous ICH on anticoagulation represents a permanent contraindication, especially with mechanical stroke prevention already in place.

Do not use "bridging" with heparin. There is no indication for any parenteral anticoagulation in this patient.

Do not add clopidogrel to aspirin long-term. DAPT increases bleeding risk without proven benefit beyond the initial post-device period 3.

Do not consider left atrial appendage closure "failure" requiring anticoagulation. Her Watchman is functioning as intended—it's a mechanical alternative to anticoagulation, not an adjunct requiring continued anticoagulation.

Alternative Scenario

If TEE reveals device-related thrombus despite aspirin, the options become extremely limited:

• Increase aspirin to 325 mg daily plus add clopidogrel 75 mg (accepting higher bleeding risk)
• Consider very short course (4-6 weeks maximum) of reduced-dose DOAC (e.g., apixaban 2.5 mg BID) with intensive neurologic monitoring, though this carries substantial rebleeding risk 4
• Surgical LAA ligation is theoretically possible but carries prohibitive operative risk

The evidence strongly supports that with confirmed successful Watchman and PFO closure, aspirin monotherapy provides adequate thromboprophylaxis while minimizing the catastrophic risk of recurrent intracranial hemorrhage 3, 4, 5.